EXECUTIVE ENGAGEMENTS
POOL
10862
Number of executives repeatedly engaged by snail & email outreach
INTERACTIONS
1303
Interactions with Platform & by Email
PARTICIPANTS
326
Unique # Participated
VALIDATIONS
82
Responses Validated*
COMPANIES
47
Responses Validated*
* Login for a full stack data experience
DATE
OCT 2022
TABLES
122
PAGES
196
EDITION
18
PRICE
USD 5450
CODE
MCP-6736
*Engagement stats are ongoing and dynamic
RESEARCH MODULES
EXECUTIVES
HIGHLIGHTS & REPORT INDEX
What`s New for 2023?
» Special coverage on Russia-Ukraine war; global inflation; easing of "zero-Covid" policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
» Global competitiveness and key competitor percentage market shares
» Market presence across multiple geographies - Strong/Active/Niche/Trivial
» Online interactive peer-to-peer collaborative bespoke updates
» Access to our digital archives and MarketGlass Research Platform
» Complimentary updates for one year
Looking Ahead to 2023
The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet. Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China’s already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.
Amid the COVID-19 crisis, the global market for Companion Diagnostics estimated at US$8 Billion in the year 2020, is projected to reach a revised size of US$19.5 Billion by 2027, growing at aCAGR of 13.5% over the period 2020-2027. Assay kits & Reagents, one of the segments analyzed in the report, is projected to record 12.6% CAGR and reach US$12.6 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Software & Services segment is readjusted to a revised 15.2% CAGR for the next 7-year period.
The Companion Diagnostics market in the U.S. is estimated at US$2.4 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$3.4 Billion by the year 2027 trailing a CAGR of 13% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 12% and 11.5% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 9.9% CAGR.
SELECT PLAYERS
Abbott Molecular; Agilent Technologies, Inc.; bioMérieux SA; Cepheid; Danaher Corporation; F. Hoffmann-La Roche Ltd.; Foundation Medicine Inc.; Laboratory Corporation of America® Holdings; Leica Biosystems Nussloch GmbH; Merck & Co. Inc.; Myriad Genetics Inc.; NeoGenomics Laboratories, Inc.; QIAGEN N.V.; Quest Diagnostics Inc.; Thermo Fischer Scientific Inc.
SEGMENTS
» Product & Service (Assay kits & Reagents, Software & Services) » Technology (Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS), Other Technologies) » Indication (Oncology, Neurology, Other Indications) » End-Use (Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs, Other End-Uses)
GEOGRAPHIES
» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World
TABLE OF CONTENTS
| I. METHODOLOGY |
| II. EXECUTIVE SUMMARY |
| 1. MARKET OVERVIEW |
| Influencer Market Insights |
| World Market Trajectories |
| Impact of Covid-19 and a Looming Global Recession |
| Companion Diagnostics: An Introductory Prelude |
| Quashing the One-Size-Fits-All Approach, CDx Wield Great Promise for Streamlined Drug Discovery & Development |
| Broader Scope and Applications Rev Up Growth Opportunities |
| Healthy Growth Projected over the Next Few Years |
| Developed Regions: Key Revenue Contributors |
| Market Witnesses Fast Paced Growth in Developing Regions |
| Northbound Trajectory in R&D Spending Creates Conducive Environment |
| Prevailing Economic Scenario Favors Funding Pattern |
| Companion Diagnostics – Global Key Competitors Percentage Market Share in 2022 (E) |
| Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E) |
| 2. FOCUS ON SELECT PLAYERS |
| 3. MARKET TRENDS & DRIVERS |
| Growing Significance of Personalized Medicine Remains a Major Market Driver |
| Emphasis on Improving Targeted Therapies with CDx Tests Steers Momentum |
| Herceptin Lays the Road for Companion Diagnostics |
| Oncology - Dominant Therapy Area for CDx |
| Rising Incidence of Cancer Propels the Need for CDx Tests |
| Technology Advancements to Widen CDx Use Case |
| PCR: Dominant Technology Type for CDx Testing |
| Next-Generation Sequencing (NGS) Gains Widespread Traction in CDx Testing |
| Significant Role of Biomarkers in Companion Diagnostics |
| Critical Healthcare Needs of Aging Population Underpin CDx Sales |
| Regulatory Scenario Favors CDx Market |
| Resolving Prevailing Challenges: Critical for Future Growth of CDx Market |
| 4. GLOBAL MARKET PERSPECTIVE |
| World Recent Past, Current & Future Analysis for Companion Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World 7-Year Perspective for Companion Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2021 & 2027 |
| World Recent Past, Current & Future Analysis for Assay kits & Reagents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World 7-Year Perspective for Assay kits & Reagents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2021 & 2027 |
| World Recent Past, Current & Future Analysis for Software & Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World 7-Year Perspective for Software & Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2021 & 2027 |
| World Recent Past, Current & Future Analysis for Polymerase Chain Reaction (PCR) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World 7-Year Perspective for Polymerase Chain Reaction (PCR) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2021 & 2027 |
| World Recent Past, Current & Future Analysis for Immunohistochemistry (IHC) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World 7-Year Perspective for Immunohistochemistry (IHC) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2021 & 2027 |
| World Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World 7-Year Perspective for In Situ Hybridization (ISH) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2021 & 2027 |
| World Recent Past, Current & Future Analysis for Next-Generation Sequencing (NGS) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World 7-Year Perspective for Next-Generation Sequencing (NGS) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2021 & 2027 |
| World Recent Past, Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World 7-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2021 & 2027 |
| World Recent Past, Current & Future Analysis for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World 7-Year Perspective for Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2021 & 2027 |
| World Recent Past, Current & Future Analysis for Neurology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World 7-Year Perspective for Neurology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2021 & 2027 |
| World Recent Past, Current & Future Analysis for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World 7-Year Perspective for Other Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2021 & 2027 |
| World Recent Past, Current & Future Analysis for Pharmaceutical & Biopharmaceutical Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World 7-Year Perspective for Pharmaceutical & Biopharmaceutical Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2021 & 2027 |
| World Recent Past, Current & Future Analysis for Reference Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World 7-Year Perspective for Reference Laboratories by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2021 & 2027 |
| World Recent Past, Current & Future Analysis for CROs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World 7-Year Perspective for CROs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2021 & 2027 |
| World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World 7-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2021 & 2027 |
| World Companion Diagnostics Market Analysis of Annual Sales in US$ Million for Years 2012 through 2027 |
| III. MARKET ANALYSIS |
| UNITED STATES |
| Companion Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2022 (E) |
| USA Recent Past, Current & Future Analysis for Companion Diagnostics by Product & Service - Assay kits & Reagents and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| USA 7-Year Perspective for Companion Diagnostics by Product & Service - Percentage Breakdown of Value Sales for Assay kits & Reagents and Software & Services for the Years 2021 & 2027 |
| USA Recent Past, Current & Future Analysis for Companion Diagnostics by Technology - Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS) and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| USA 7-Year Perspective for Companion Diagnostics by Technology - Percentage Breakdown of Value Sales for Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS) and Other Technologies for the Years 2021 & 2027 |
| USA Recent Past, Current & Future Analysis for Companion Diagnostics by Indication - Oncology, Neurology and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| USA 7-Year Perspective for Companion Diagnostics by Indication - Percentage Breakdown of Value Sales for Oncology, Neurology and Other Indications for the Years 2021 & 2027 |
| USA Recent Past, Current & Future Analysis for Companion Diagnostics by End-Use - Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| USA 7-Year Perspective for Companion Diagnostics by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs and Other End-Uses for the Years 2021 & 2027 |
| CANADA |
| Canada Recent Past, Current & Future Analysis for Companion Diagnostics by Product & Service - Assay kits & Reagents and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Canada 7-Year Perspective for Companion Diagnostics by Product & Service - Percentage Breakdown of Value Sales for Assay kits & Reagents and Software & Services for the Years 2021 & 2027 |
| Canada Recent Past, Current & Future Analysis for Companion Diagnostics by Technology - Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS) and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Canada 7-Year Perspective for Companion Diagnostics by Technology - Percentage Breakdown of Value Sales for Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS) and Other Technologies for the Years 2021 & 2027 |
| Canada Recent Past, Current & Future Analysis for Companion Diagnostics by Indication - Oncology, Neurology and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Canada 7-Year Perspective for Companion Diagnostics by Indication - Percentage Breakdown of Value Sales for Oncology, Neurology and Other Indications for the Years 2021 & 2027 |
| Canada Recent Past, Current & Future Analysis for Companion Diagnostics by End-Use - Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Canada 7-Year Perspective for Companion Diagnostics by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs and Other End-Uses for the Years 2021 & 2027 |
| JAPAN |
| Companion Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2022 (E) |
| Japan Recent Past, Current & Future Analysis for Companion Diagnostics by Product & Service - Assay kits & Reagents and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Japan 7-Year Perspective for Companion Diagnostics by Product & Service - Percentage Breakdown of Value Sales for Assay kits & Reagents and Software & Services for the Years 2021 & 2027 |
| Japan Recent Past, Current & Future Analysis for Companion Diagnostics by Technology - Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS) and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Japan 7-Year Perspective for Companion Diagnostics by Technology - Percentage Breakdown of Value Sales for Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS) and Other Technologies for the Years 2021 & 2027 |
| Japan Recent Past, Current & Future Analysis for Companion Diagnostics by Indication - Oncology, Neurology and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Japan 7-Year Perspective for Companion Diagnostics by Indication - Percentage Breakdown of Value Sales for Oncology, Neurology and Other Indications for the Years 2021 & 2027 |
| Japan Recent Past, Current & Future Analysis for Companion Diagnostics by End-Use - Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Japan 7-Year Perspective for Companion Diagnostics by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs and Other End-Uses for the Years 2021 & 2027 |
| CHINA |
| Companion Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2022 (E) |
| China Recent Past, Current & Future Analysis for Companion Diagnostics by Product & Service - Assay kits & Reagents and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| China 7-Year Perspective for Companion Diagnostics by Product & Service - Percentage Breakdown of Value Sales for Assay kits & Reagents and Software & Services for the Years 2021 & 2027 |
| China Recent Past, Current & Future Analysis for Companion Diagnostics by Technology - Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS) and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| China 7-Year Perspective for Companion Diagnostics by Technology - Percentage Breakdown of Value Sales for Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS) and Other Technologies for the Years 2021 & 2027 |
| China Recent Past, Current & Future Analysis for Companion Diagnostics by Indication - Oncology, Neurology and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| China 7-Year Perspective for Companion Diagnostics by Indication - Percentage Breakdown of Value Sales for Oncology, Neurology and Other Indications for the Years 2021 & 2027 |
| China Recent Past, Current & Future Analysis for Companion Diagnostics by End-Use - Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| China 7-Year Perspective for Companion Diagnostics by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs and Other End-Uses for the Years 2021 & 2027 |
| EUROPE |
| Companion Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2022 (E) |
| Europe Recent Past, Current & Future Analysis for Companion Diagnostics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| Europe 7-Year Perspective for Companion Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2021 & 2027 |
| Europe Recent Past, Current & Future Analysis for Companion Diagnostics by Product & Service - Assay kits & Reagents and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Europe 7-Year Perspective for Companion Diagnostics by Product & Service - Percentage Breakdown of Value Sales for Assay kits & Reagents and Software & Services for the Years 2021 & 2027 |
| Europe Recent Past, Current & Future Analysis for Companion Diagnostics by Technology - Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS) and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Europe 7-Year Perspective for Companion Diagnostics by Technology - Percentage Breakdown of Value Sales for Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS) and Other Technologies for the Years 2021 & 2027 |
| Europe Recent Past, Current & Future Analysis for Companion Diagnostics by Indication - Oncology, Neurology and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Europe 7-Year Perspective for Companion Diagnostics by Indication - Percentage Breakdown of Value Sales for Oncology, Neurology and Other Indications for the Years 2021 & 2027 |
| Europe Recent Past, Current & Future Analysis for Companion Diagnostics by End-Use - Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Europe 7-Year Perspective for Companion Diagnostics by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs and Other End-Uses for the Years 2021 & 2027 |
| FRANCE |
| Companion Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2022 (E) |
| France Recent Past, Current & Future Analysis for Companion Diagnostics by Product & Service - Assay kits & Reagents and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| France 7-Year Perspective for Companion Diagnostics by Product & Service - Percentage Breakdown of Value Sales for Assay kits & Reagents and Software & Services for the Years 2021 & 2027 |
| France Recent Past, Current & Future Analysis for Companion Diagnostics by Technology - Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS) and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| France 7-Year Perspective for Companion Diagnostics by Technology - Percentage Breakdown of Value Sales for Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS) and Other Technologies for the Years 2021 & 2027 |
| France Recent Past, Current & Future Analysis for Companion Diagnostics by Indication - Oncology, Neurology and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| France 7-Year Perspective for Companion Diagnostics by Indication - Percentage Breakdown of Value Sales for Oncology, Neurology and Other Indications for the Years 2021 & 2027 |
| France Recent Past, Current & Future Analysis for Companion Diagnostics by End-Use - Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| France 7-Year Perspective for Companion Diagnostics by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs and Other End-Uses for the Years 2021 & 2027 |
| GERMANY |
| Companion Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2022 (E) |
| Germany Recent Past, Current & Future Analysis for Companion Diagnostics by Product & Service - Assay kits & Reagents and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Germany 7-Year Perspective for Companion Diagnostics by Product & Service - Percentage Breakdown of Value Sales for Assay kits & Reagents and Software & Services for the Years 2021 & 2027 |
| Germany Recent Past, Current & Future Analysis for Companion Diagnostics by Technology - Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS) and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Germany 7-Year Perspective for Companion Diagnostics by Technology - Percentage Breakdown of Value Sales for Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS) and Other Technologies for the Years 2021 & 2027 |
| Germany Recent Past, Current & Future Analysis for Companion Diagnostics by Indication - Oncology, Neurology and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Germany 7-Year Perspective for Companion Diagnostics by Indication - Percentage Breakdown of Value Sales for Oncology, Neurology and Other Indications for the Years 2021 & 2027 |
| Germany Recent Past, Current & Future Analysis for Companion Diagnostics by End-Use - Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Germany 7-Year Perspective for Companion Diagnostics by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs and Other End-Uses for the Years 2021 & 2027 |
| ITALY |
| Italy Recent Past, Current & Future Analysis for Companion Diagnostics by Product & Service - Assay kits & Reagents and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Italy 7-Year Perspective for Companion Diagnostics by Product & Service - Percentage Breakdown of Value Sales for Assay kits & Reagents and Software & Services for the Years 2021 & 2027 |
| Italy Recent Past, Current & Future Analysis for Companion Diagnostics by Technology - Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS) and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Italy 7-Year Perspective for Companion Diagnostics by Technology - Percentage Breakdown of Value Sales for Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS) and Other Technologies for the Years 2021 & 2027 |
| Italy Recent Past, Current & Future Analysis for Companion Diagnostics by Indication - Oncology, Neurology and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Italy 7-Year Perspective for Companion Diagnostics by Indication - Percentage Breakdown of Value Sales for Oncology, Neurology and Other Indications for the Years 2021 & 2027 |
| Italy Recent Past, Current & Future Analysis for Companion Diagnostics by End-Use - Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Italy 7-Year Perspective for Companion Diagnostics by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs and Other End-Uses for the Years 2021 & 2027 |
| UNITED KINGDOM |
| Companion Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2022 (E) |
| UK Recent Past, Current & Future Analysis for Companion Diagnostics by Product & Service - Assay kits & Reagents and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| UK 7-Year Perspective for Companion Diagnostics by Product & Service - Percentage Breakdown of Value Sales for Assay kits & Reagents and Software & Services for the Years 2021 & 2027 |
| UK Recent Past, Current & Future Analysis for Companion Diagnostics by Technology - Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS) and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| UK 7-Year Perspective for Companion Diagnostics by Technology - Percentage Breakdown of Value Sales for Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS) and Other Technologies for the Years 2021 & 2027 |
| UK Recent Past, Current & Future Analysis for Companion Diagnostics by Indication - Oncology, Neurology and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| UK 7-Year Perspective for Companion Diagnostics by Indication - Percentage Breakdown of Value Sales for Oncology, Neurology and Other Indications for the Years 2021 & 2027 |
| UK Recent Past, Current & Future Analysis for Companion Diagnostics by End-Use - Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| UK 7-Year Perspective for Companion Diagnostics by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs and Other End-Uses for the Years 2021 & 2027 |
| REST OF EUROPE |
| Rest of Europe Recent Past, Current & Future Analysis for Companion Diagnostics by Product & Service - Assay kits & Reagents and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of Europe 7-Year Perspective for Companion Diagnostics by Product & Service - Percentage Breakdown of Value Sales for Assay kits & Reagents and Software & Services for the Years 2021 & 2027 |
| Rest of Europe Recent Past, Current & Future Analysis for Companion Diagnostics by Technology - Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS) and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of Europe 7-Year Perspective for Companion Diagnostics by Technology - Percentage Breakdown of Value Sales for Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS) and Other Technologies for the Years 2021 & 2027 |
| Rest of Europe Recent Past, Current & Future Analysis for Companion Diagnostics by Indication - Oncology, Neurology and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of Europe 7-Year Perspective for Companion Diagnostics by Indication - Percentage Breakdown of Value Sales for Oncology, Neurology and Other Indications for the Years 2021 & 2027 |
| Rest of Europe Recent Past, Current & Future Analysis for Companion Diagnostics by End-Use - Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of Europe 7-Year Perspective for Companion Diagnostics by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs and Other End-Uses for the Years 2021 & 2027 |
| ASIA-PACIFIC |
| Companion Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2022 (E) |
| Asia-Pacific Recent Past, Current & Future Analysis for Companion Diagnostics by Product & Service - Assay kits & Reagents and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Asia-Pacific 7-Year Perspective for Companion Diagnostics by Product & Service - Percentage Breakdown of Value Sales for Assay kits & Reagents and Software & Services for the Years 2021 & 2027 |
| Asia-Pacific Recent Past, Current & Future Analysis for Companion Diagnostics by Technology - Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS) and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Asia-Pacific 7-Year Perspective for Companion Diagnostics by Technology - Percentage Breakdown of Value Sales for Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS) and Other Technologies for the Years 2021 & 2027 |
| Asia-Pacific Recent Past, Current & Future Analysis for Companion Diagnostics by Indication - Oncology, Neurology and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Asia-Pacific 7-Year Perspective for Companion Diagnostics by Indication - Percentage Breakdown of Value Sales for Oncology, Neurology and Other Indications for the Years 2021 & 2027 |
| Asia-Pacific Recent Past, Current & Future Analysis for Companion Diagnostics by End-Use - Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Asia-Pacific 7-Year Perspective for Companion Diagnostics by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs and Other End-Uses for the Years 2021 & 2027 |
| REST OF WORLD |
| Rest of World Recent Past, Current & Future Analysis for Companion Diagnostics by Product & Service - Assay kits & Reagents and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of World 7-Year Perspective for Companion Diagnostics by Product & Service - Percentage Breakdown of Value Sales for Assay kits & Reagents and Software & Services for the Years 2021 & 2027 |
| Rest of World Recent Past, Current & Future Analysis for Companion Diagnostics by Technology - Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS) and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of World 7-Year Perspective for Companion Diagnostics by Technology - Percentage Breakdown of Value Sales for Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS) and Other Technologies for the Years 2021 & 2027 |
| Rest of World Recent Past, Current & Future Analysis for Companion Diagnostics by Indication - Oncology, Neurology and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of World 7-Year Perspective for Companion Diagnostics by Indication - Percentage Breakdown of Value Sales for Oncology, Neurology and Other Indications for the Years 2021 & 2027 |
| Rest of World Recent Past, Current & Future Analysis for Companion Diagnostics by End-Use - Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of World 7-Year Perspective for Companion Diagnostics by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs and Other End-Uses for the Years 2021 & 2027 |
| IV. COMPETITION |
PREVIEW REPORT
Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.
What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com